tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Keloid D007627 12 associated lipids
Nephritis D009393 19 associated lipids
Food Hypersensitivity D005512 7 associated lipids
Respiration Disorders D012120 5 associated lipids
Thymus Neoplasms D013953 15 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Facial Neoplasms D005153 3 associated lipids
Dysgammaglobulinemia D004406 3 associated lipids
Influenza, Human D007251 11 associated lipids
Immune System Diseases D007154 3 associated lipids
Headache D006261 4 associated lipids
Cystitis D003556 23 associated lipids
Sarcoma, Kaposi D012514 6 associated lipids
HIV Infections D015658 20 associated lipids
Drug Eruptions D003875 30 associated lipids
Folliculitis D005499 7 associated lipids
Blindness D001766 6 associated lipids
Oliguria D009846 2 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Wiebe C et al. Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development. 2017 J. Am. Soc. Nephrol. pmid:28729289
Abongwa C et al. Successful treatment of tacrolimus-related pure red cell aplasia and autoimmune hemolytic anemia with rituximab in a pediatric cardiac transplant patient. 2017 Pediatr Blood Cancer pmid:28598573
Wu Z et al. FOXP3 rs3761548 polymorphism is associated with tacrolimus-induced acute nephrotoxicity in renal transplant patients. 2017 Eur. J. Clin. Pharmacol. pmid:27747372
Torres IB et al. Tacrolimus and mycophenolate regimen and subclinical tubulo-interstitial inflammation in low immunological risk renal transplants. 2017 Transpl. Int. pmid:28667664
Nakagawa K et al. Immunosuppressive treatment using tacrolimus promotes pregnancy outcome in infertile women with repeated implantation failures. 2017 Am. J. Reprod. Immunol. pmid:28466977
Harada S et al. Complete remission of angiolymphoid hyperplasia with eosinophilia using topical tacrolimus. 2017 Eur J Dermatol pmid:28007668
Bellon H et al. The Effect of Immunosuppression on Airway Integrity. 2017 Transplantation pmid:28471870
Ferjani H et al. Beneficial effects of mycophenolate mofetil on cardiotoxicity induced by tacrolimus in wistar rats. 2017 Exp. Biol. Med. (Maywood) pmid:26582055
Solari S et al. Sublingual tacrolimus administration provides similar drug exposure to per-oral route employing lower doses in liver transplantation: a pilot study. 2017 Aliment. Pharmacol. Ther. pmid:28261844
Cui W et al. Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy. 2017 Braz. J. Med. Biol. Res. pmid:28355356
Siponen M et al. Topical tacrolimus, triamcinolone acetonide, and placebo in oral lichen planus: a pilot randomized controlled trial. 2017 Oral Dis pmid:28168769
Vanhove T et al. Response to: 'Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'. 2017 Br J Clin Pharmacol pmid:28168728
Gao L et al. Low incidence of acute graft-versus-host disease with short-term tacrolimus in haploidentical hematopoietic stem cell transplantation. 2017 Leuk. Res. pmid:28273549
Aschauer C et al. Positioning of Tacrolimus for the Treatment of Diabetic Nephropathy Based on Computational Network Analysis. 2017 PLoS ONE pmid:28060893
Dong Y et al. Risk Factors, Clinical Features, and Treatment Outcomes of Recurrent Mooren Ulcers in China. 2017 Cornea pmid:28060068
Kim YK et al. New tablet formulation of tacrolimus with smaller interindividual variability may become a better treatment option than the conventional capsule formulation in organ transplant patients. 2017 Drug Des Devel Ther pmid:29033547
Tamura M et al. [A case of anti-PL-7 antibody positive polymyositis with thrombotic microangiopathy]. 2017 Nihon Rinsho Meneki Gakkai Kaishi pmid:29367529
Dutta D et al. Recruitment of calcineurin to the TCR positively regulates T cell activation. 2017 Nat. Immunol. pmid:27941787
Naicker D et al. Nationwide conversion to generic tacrolimus in pediatric kidney transplant recipients. 2017 Pediatr. Nephrol. pmid:28660366
Gatault P et al. Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study. 2017 Am. J. Transplant. pmid:27862923